Note 14 - Segment Information: Schedule of Segment Reporting Information, by Segment (Tables)

12 Months Ended

Apr. 30, 2015

Tables/Schedules

Schedule of Segment Reporting Information, by Segment

	Fiscal Years Ended April 30,
	2015	2014
Revenues:
Chinese medicine – third party	$       2,333,789	$    2,429,468
Chinese medicine – related party	0	0
Total Chinese medicine	2,333,789	2,429,468
Stevioside – third party	9,096,329	6,738,685
Stevioside – related party	6,081,939	3,705,504
Total Stevioside	15,178,268	10,444,189
Total segment and consolidated revenues	$     17,512,057	$ 12,873,657
Interest expense:
Chinese medicine	$                       0	$                    0
Stevioside	(368,775)	120,144
Corporate and other	0	0
Total segment and consolidated interest expense	$         (368,775)	$       120,144
Depreciation and amortization:
Chinese medicine	$           531,343	$       164,122
Stevioside	1,558,391	2,000,460
Corporate and other	325,175	0
Total segment and consolidated depreciation and amortization	$       2,414,909	$    2,164,582
Loss before income taxes:
Chinese medicine	$           393,308	$         52,141
Stevioside	3,913,729	2,961,882
Corporate and other	105,761	51,798
Total consolidated loss before income taxes	$       4,412,798	$    3,065,821